• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Enantiomerically pure 1,3,2-dioxaborolanes: new reagents for the hydroboration of alkynes
  Chem. Commun., 1998, 2651-2652
• 3. Fe3O4@SiO2 core–shell nanoparticles for biomedical purposes: adverse effects on blood cells?
  C. Achilli,G. F. Guidetti,A. Ciana,D. Capsoni,G. Minetti Biomater. Sci., 2016,4, 1417-1421
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Pyridinylpiperazines

Introduction to 6-(4-methylpiperazin-1-yl)pyridin-2-amine (CAS No. 54132-20-6)

6-(4-methylpiperazin-1-yl)pyridin-2-amine, identified by the Chemical Abstracts Service Number (CAS No.) 54132-20-6, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic amine derivative has garnered attention due to its structural features and potential biological activities, making it a subject of extensive study in drug discovery and development.

The molecular structure of 6-(4-methylpiperazin-1-yl)pyridin-2-amine consists of a pyridine ring fused with a piperazine moiety, which is a common pharmacophore in many bioactive molecules. The presence of the 4-methylpiperazine substituent enhances the compound's solubility and bioavailability, while the pyridine ring contributes to its interaction with various biological targets. This unique combination has positioned it as a valuable scaffold for designing novel therapeutic agents.

In recent years, there has been growing interest in exploring the pharmacological properties of 6-(4-methylpiperazin-1-yl)pyridin-2-amine. Studies have indicated that this compound exhibits promising activities in several disease models, including central nervous system (CNS) disorders and inflammatory conditions. The piperazine moiety, in particular, is known for its ability to modulate neurotransmitter systems, which makes it a attractive candidate for developing drugs targeting neurological diseases.

One of the most compelling aspects of 6-(4-methylpiperazin-1-yl)pyridin-2-amine is its potential as an intermediate in the synthesis of more complex pharmacological entities. Researchers have leveraged its structural framework to develop derivatives with enhanced binding affinity and selectivity for specific biological targets. For instance, modifications at the pyridine ring have been explored to improve interactions with receptors such as serotonin and dopamine transporters, which are crucial in the treatment of depression and schizophrenia.

The synthesis of 6-(4-methylpiperazin-1-yl)pyridin-2-amine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including catalytic hydrogenation and nucleophilic substitution reactions, have been employed to construct the desired molecular framework efficiently. These synthetic strategies not only highlight the compound's synthetic accessibility but also underscore the expertise required in medicinal chemistry for its production.

Recent advancements in computational chemistry have further accelerated the study of 6-(4-methylpiperazin-1-yl)pyridin-2-amine. Molecular modeling techniques have been used to predict its binding modes with biological targets, providing insights into its mechanism of action. These computational studies have complemented experimental investigations, offering a holistic understanding of the compound's pharmacological profile. Such integrative approaches are essential for optimizing drug candidates and advancing them towards clinical development.

The therapeutic potential of 6-(4-methylpiperazin-1-yl)pyridin-2-amine has also been explored in preclinical models. Initial studies have demonstrated its efficacy in reducing inflammation and modulating pain perception, suggesting its utility in treating chronic inflammatory diseases and neuropathic pain conditions. Additionally, its interaction with enzymes and receptors involved in metabolic pathways has raised interest in its potential role in managing metabolic disorders.

As research continues to unfold, the applications of 6-(4-methylpiperazin-1-yipyridin -2 -amine) are expected to expand further. The integration of cutting-edge technologies such as CRISPR gene editing and artificial intelligence-driven drug discovery platforms holds promise for uncovering new therapeutic modalities involving this compound. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation, translating these findings into tangible clinical benefits for patients worldwide.

In conclusion, 6-(4-methyl-piperazin -1 -yipyridin -2 -amine (CAS No. 54132 -20 -6) represents a fascinating compound with diverse pharmacological applications. Its unique structural features, coupled with emerging research findings, position it as a cornerstone in modern drug discovery efforts aimed at addressing complex diseases. As scientific understanding evolves, 6-(4-methyl-piperazin -1 -yipyridin -2 -amine) is poised to play an increasingly pivotal role in shaping future therapeutic strategies across multiple medical disciplines.

• 64728-49-0(1,4-Di(2-pyridyl)piperazine)
• 126653-00-7(1-Piperazine-1-yl-isoquinoline)
• 34803-66-2(1-(2-Pyridyl)piperazine)
• 36075-06-6(2-Diethylaminopyridine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)